10 Penny Stocks That Will Skyrocket

7. Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Stock Upside Potential as of July 30: 211.61%

Share Price as of July 30: $2.84

Number of Hedge Fund Holders: 20

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the penny stocks that will skyrocket. On July 11, BofA Securities initiated coverage of the stock with a “Buy” rating and an $8 price target. The positive stance comes as the research firm remains buoyed by the company’s Taysha gene therapy TSHA-102 under development for Rett Syndrome.

The research firm believes TSHA-102 has the potential to become the first approved disease-modifying treatment for the severe neurodevelopmental disease. Clinical trials have already demonstrated that the therapy has the potential to help patients regain or achieve developmental milestones.

Taysha Gene Therapies has already reached an alignment with the US Food and Drug Administration on a pivotal trial design for TSHA-102. The company plans to initiate a trial in the third quarter of 2023. BofA Securities views the candidate treatment as a commercially attractive opportunity.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a clinical-stage biotechnology company that develops and commercializes gene therapies for severe monogenic diseases of the central nervous system (CNS). It seeks to address unmet medical needs by developing transformative medicines for these diseases. Its approach centers on using adeno-associated virus (AAV)-based gene therapies.